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Abstract
Background—Analysis of a large cohort of business travelers will help clinicians focus on 
frequent and serious illnesses. We aimed to describe travel-related health problems in business 
travelers.
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Methods—GeoSentinel Surveillance Network consists of 64 travel and tropical medicine clinics 
in 29 countries; descriptive analysis was performed on ill business travelers, defined as persons 
traveling for work, evaluated after international travel 1 January 1997 through 31 December 2014.
Results—Among 12 203 business travelers seen 1997–2014 (14 045 eligible diagnoses), the 
majority (97%) were adults aged 20–64 years; most (74%) reported from Western Europe or North 
America; two-thirds were male. Most (86%) were outpatients. Fewer than half (45%) reported a 
pre-travel healthcare encounter. Frequent regions of exposure were sub-Saharan Africa (37%), 
Southeast Asia (15%) and South Central Asia (14%). The most frequent diagnoses were malaria 
(9%), acute unspecified diarrhea (8%), viral syndrome (6%), acute bacterial diarrhea (5%) and 
chronic diarrhea (4%). Species was reported for 973 (90%) of 1079 patients with malaria, 
predominantly Plasmodium falciparum acquired in sub-Saharan Africa. Of 584 (54%) with 
malaria chemoprophylaxis information, 92% took none or incomplete courses. Thirteen deaths 
were reported, over half of which were due to malaria; others succumbed to pneumonia, typhoid 
fever, rabies, melioidosis and pyogenic abscess.
Conclusions—Diarrheal illness was a major cause of morbidity. Malaria contributed substantial 
morbidity and mortality, particularly among business travelers to sub-Saharan Africa. Underuse or 
non-use of chemoprophylaxis contributed to malaria cases. Deaths in business travelers could be 
reduced by improving adherence to malaria chemoprophylaxis and targeted vaccination for 
vaccine-preventable diseases. Pre-travel advice is indicated for business travelers and is currently 
under-utilized and needs improvement.
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Background
Globally, business travel comprises ~14% of all international travel.1 The destination, 
frequency and duration of travel among business travelers are highly variable.2 A review of 
more than 800 000 international trips by employees and reports of medical assistance 
provided to 48 multinational corporations found that 26% of corporate travelers had at least 
three international trips per year, 17% traveled at least 30 days during the year, and 11% had 
at least one trip with a duration of 30 days or more; this cohort reported 1188 illnesses.3
Illness in an employee while traveling has additional consequences that may be less relevant 
if in their country of residence (with respect to healthcare, reduced productivity as harder to 
find replacement, potential repatriation).4 Other than the study described above, most 
analyses of illness in these travelers have focused on a single company or small cohorts. The 
GeoSentinel Surveillance Network consists of 64 travel and tropical medicine clinics in 29 
countries with representation from six continents, arguably provides one of the largest global 
sample of business travelers, and allows a systematic analysis of their health problems.5 We 
describe the travel patterns of ill business travelers entered in the database and identify 
illnesses that affect this group.
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Methods
GeoSentinel Surveillance Network data on travelers seen after travel from 1997 through 
2014 were analyzed. GeoSentinel captures data on travelers that have crossed an 
international border and have been evaluated for a presumed travel-associated illness.5 
Business travelers who presented to a GeoSentinel site and who had at least one travel-
related diagnosis were included. We defined business travel as ‘travel for the purpose of 
working, (encompassing a range of occupational-related travel, including corporate travel, 
field work) or attending a meeting or other work-related event such as conferences; travelers 
accompanying the business traveler (often family members) are also defined as ‘business’ 
travelers. Patients missing data on age or under the age of 20 years at time of diagnosis were 
excluded from analysis.
Final diagnoses are assigned by the clinician and chosen from a list of >500 standard 
GeoSentinel diagnosis codes, which may be etiologic (e.g. falciparum malaria, influenza, 
Salmonella Typhi) or syndromic (e.g. diarrhea, fever, rash).5 Diagnosis codes were also 
categorized into broad syndrome groups.5 Each traveler may have more than one diagnosis, 
and each diagnosis is recorded as confirmed, probable or suspected. We included only 
diagnoses that were confirmed or probable, and were determined by the clinician to be 
‘travel-related.’ We excluded the diagnoses ‘healthy,’ ‘lost to follow up’ and ‘screening’; 
non-infectious diagnoses not directly related to travel (Appendix); and diagnoses with 
uncertain relationship to travel or uncertain time and place of exposure (Appendix).
We used descriptive analyses to describe overall demographics and itinerary characteristics 
of business travelers seen after travel, as well as diagnoses and seriousness (outpatient/
inpatient/death). We distinguished diagnoses among expatriates (designated by reporting 
sites for persons living in a destination country with an independent residence, using mostly 
the infrastructure used by local residents of the same economic class, independent of 
duration of residence) from non-expatriate business travelers. We also describe the top 
diagnoses geographically by region of exposure according to modified United Nations’ 
world regions; we combined Australia, New Zealand, North America and Western Europe 
since each held high human development index and represented less frequent locations of 
illness acquisition.5
GeoSentinel’s data collection and analysis protocol has been reviewed by a human subjects 
advisor for the Centers for Disease Control and Prevention and is classified as public health 
surveillance; for this reason, it has been determined that IRB review is not required.
Results
This analysis included 12 203 ill business travelers (14 045 confirmed or probable 
diagnoses) who presented post-travel to a GeoSentinel clinic (Table 1). Median age was 40 
years and 11 779 (97%) travelers were aged 20–64 years; two-thirds were male. Most were 
seen as outpatients; fewer than half reported a pre-travel health encounter. Three-quarters 
were reported from Western Europe or North America. Frequent regions of exposure were 
sub-Saharan Africa (37%), Southeast Asia (15%), South Central Asia (14%), South America 
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(7%), Northeast Asia (6%) and Central America (4%). Twelve percent were expatriate 
business travelers.
Syndromes and diagnoses
The most frequently reported disease syndromes among the 14 045 total diagnoses were 
acute diarrhea (24%), febrile/systemic illness (24%), dermatologic (13%), respiratory (10%), 
other gastrointestinal problems (8%) and chronic diarrhea (8%) (Table 2). The most frequent 
diagnoses were malaria (9%), acute unspecified diarrhea (8%), viral syndrome (6%), acute 
bacterial diarrhea (5%) and chronic diarrhea (4%). Among non-expatriate business travelers, 
the most frequent diagnoses were acute unspecified diarrhea, viral syndrome, acute bacterial 
diarrhea, chronic diarrhea and Plasmodium falciparum malaria (each <10% of total) (Table 2 
Among expatriate business travelers, the most frequent diagnosis was P. falciparum malaria 
(6%), followed by viral syndrome, chronic diarrhea, acute unspecified diarrhea, dengue, 
Blastocystis and upper respiratory tract infection (3% each).
Analysis by regions highlighted the frequency of diagnosis of P. falciparum malaria for sub-
Saharan Africa (13% of diagnoses from the region) and P. vivax malaria for Oceania (12%) 
(Table 3). Uncomplicated dengue infection was the most frequent specific diagnosis for the 
Caribbean (9%); dog bite for Eastern Europe (9%). For the combined group that included 
Australia, New Zealand, North America and Western Europe, the most frequent diagnosis 
was upper respiratory tract infection (8%). Acute unspecified diarrhea was the most frequent 
diagnosis for the remaining regions, ranging from 10% to 19% of diagnoses (Table 3). Acute 
bacterial diarrhea and chronic diarrhea of unknown cause were frequent diagnoses for many 
regions.
Malaria diagnoses
Among 1079 patients with malaria, 973 had species reported (90%); 706 (65%) were 
infected with P. falciparum, 171 (15%) with P. vivax, 49 (5%) with P. ovale, 29 (3%) with P. 
malariae, 1 (<1%) with P. knowlesi, and 17 (2%) with mixed infections. The majority of 
1079 had exposure in sub-Saharan Africa (79%); other exposure regions included Southeast 
Asia (8%), South Central Asia (4%), Oceania (3%), South America (2%) and North Africa 
(2%) (Table 4). Of 584 (54%) with chemoprophylaxis information, 519 (89%) took no 
chemoprophylaxis and 19 (3%) took incomplete chemoprophylaxis. There were 112 patients 
with severe malaria (46 cerebral). Among 103 severe cases with species available, 100 had P. 
falciparum (one co-infected with P. ovale) and three had P. vivax. All severe malaria cases 
had exposure in Africa except for two P. vivax cases (acquired in India and Myanmar) and 
one P. falciparum cases (acquired in Guyana). Among the 1079 patients with malaria, 589 
(55%) were hospitalized and 466 (43%) reported pre-travel encounters. Seven patients died; 
all malaria fatalities with species information were due to P. falciparum (Table 5).
Species distributions for the regions are presented in Table 4. Plasmodium falciparum was 
the predominant species acquired in Africa, and P. vivax was the main species acquired in 
other regions.
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Deaths
Thirteen deaths occurred in business travelers seen after travel, of which 7 (54%) were from 
malaria. All but two fatalities occurred in male travelers. Age ranged from 24 to 82 years. 
Other causes of deaths are shown in Table 5.
Vaccine-preventable diseases
A total of 847 potentially vaccine-preventable diagnoses (7% of total diagnoses) were 
identified. The most frequently recorded were 320 influenza and influenza-like illness (38% 
of potential VPD), 200 animal exposure with potential for rabies (24%), 124 bacterial lobar 
pneumonia without specified organism (15%) and 56 typhoid (7%). There were 32 cases of 
hepatitis A, nine cases of hepatitis B, and 35 cases of acute unspecified hepatitis. Also 
identified were measles (8), mumps (2), rubella (5), pertussis (15), varicella (13), zoster (16), 
bacterial meningitis (3), and one case each of meningitis due to Haemophilus influenzae and 
Streptococcus pneumoniae. One case of tick-borne encephalitis was reported, as were an 
additional six cases of acute encephalitis without proven viral etiology. No cases of Japanese 
encephalitis or yellow fever were identified.
Sexually transmitted infections
There were 213 potential sexually transmitted infection (STI) diagnoses (2% of total 
diagnoses), most frequently acute human immunodeficiency virus (HIV; n = 45), scabies (n 
= 40), herpes simplex virus (HSV; n = 27), and syphilis (n = 22). There were also cases of 
pelvic inflammatory disease/vaginitis/cervicitis/endometritis (n = 18), <5 cases each of 
Chlamydia, gonorrhea, genital warts, genital ulcer, molluscum contagiosum, Trichomonas 
vaginalis and nine cases of unspecified STI.
Discussion
Our analysis shows a broad spectrum of illness related to business travel. Malaria diagnoses 
comprised 7% and 13% of ill returning non-expatriate and expatriate business travelers, 
respectively. Notably, half of the deaths reported in this population were due to malaria. We 
also found a large number of potentially vaccine-preventable diseases. Furthermore, we 
established gastrointestinal diagnoses as the most frequent diagnoses related to business 
travel. These results underscore the need to promote pre-travel preparation – in our analysis, 
less than half of the ill presenting business travelers reported a pre-travel medical 
consultation.
It is in the best interest of employers to ensure the health of their employees working 
internationally. Corporations sending staff overseas usually are expected to cover the costs of 
providing effective health education, vaccination and risk mitigation programs,3 either via a 
contractual arrangement with a provider organization or via an on-site occupational health 
clinic.6 A company culture that focuses on health, safety and security can contribute 
positively to high knowledge scores about health risks among business travelers.7 
Additionally, corporations may be legally liable.6 Not specifically addressed, but also to be 
considered, are the consequences from acquisition of infectious diseases that are potentially 
transmissible to the employees’ families and home and work communities. Consequently, 
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some large corporations now require pre-travel medical consultation before international 
trips.4 Despite this trend, several reports have identified business travelers as a major risk 
group for acquiring malaria.8–14 An analysis in China of 1 420 imported malaria cases found 
overseas workers accounted for 82%; complications occurred in 8% and 12 died.8 Another 
report11 described almost 8000 labor-related P. falciparum infections acquired in Africa, 
with increased cases likely related to recent business contracts between China and Africa 
combined with a lack of malaria awareness and prevention among this group. In the US, 
business was found to be the purpose of travel in 19% of fatal malaria cases.14
Our results underscore the importance of malaria as a cause of death in business travelers. 
Long-term business travelers, compared with short-term, have been shown to be more likely 
to have P. falciparum or P. vivax malaria,9 but even short-term, frequent business travelers 
can have a high cumulative risk. A recent analysis found that the pre-travel consultation was 
associated with a lower proportion of P. falciparum malaria morbidity and less severe disease 
in travelers, including business travelers.10 Occupational medicine advisors and travel 
medicine experts are, however, confronted with challenges in malaria prevention in this 
group. Adherence to personal protection measures and chemoprophylaxis, particularly in 
long-term and frequent business travelers, is a major hurdle15,16 and requires constant audit. 
Some large companies have initiated innovative approaches involving adherence and 
motivator enablers to overcome noncompliance, including urine tests to verify intake of 
chemoprophylaxis.17
Dengue was diagnosed much less frequently than malaria in this population, possibly due to 
the self-limited nature of dengue or the short incubation of dengue that may have led to 
evaluation during the trip and not captured by GeoSentinel sites. Although some business 
travelers work primarily in urban areas, these are still sites of active dengue transmission in 
tropical and subtropical countries, and business travelers are expected to be at risk for 
dengue. To date, studies of dengue fever or seroconversion in travelers generally have not 
analyzed reason for travel for those infected; thus, there are currently no systematically 
collected data on risk to business travelers relative to other travelers.
The frequency of vaccine-preventable diseases diagnosed in business travelers raises concern 
that business travelers underestimate the risk of these potentially preventable diseases. Prior 
GeoSentinel analyses of vaccine-preventable diseases found that travel for business was 
associated with a diagnosis of influenza.18 Our results affirm that influenza-like illness is a 
frequent diagnosis in business travelers. Although no cases of yellow fever were reported in 
the GeoSentinel Surveillance Network, the recent acquisition of yellow fever by numerous 
Chinese nationals working in Angola, and returning to parts of China that may be receptive 
to yellow fever introduction, is a reminder of the role that corporations should play in 
ensuring the health of their employees and in averting a potential public health disaster.19 
Notably, the estimated incidence of animal-related exposures requiring rabies post-exposure 
prophylaxis is 1.3 per 1 000 per month in expatriates,20 and among 60 cases of rabies in 
international travelers reported from 1990 to 2012, 10 were in business and expatriate 
travelers.21 Along with our results, evidence has accumulated regarding rabies risk in 
business travelers, and advice regarding rabies risk should be provided systematically at pre-
travel encounters. Given the unreliable access to rabies vaccine and immune globulin in 
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many areas, and in consideration of cumulative exposure risk, preventive pre-travel 
vaccination may be indicated.
Consumption of contaminated food/drink is a frequent route of exposure for ill business 
travelers. Generally the estimated incidence of travelers’ diarrhea has declined from 65% 20 
years ago to 10–40% currently, attributed to improved economic development, tourism 
infrastructure, availability of bottled water and greater awareness of risk.22 However, 
gastrointestinal problems, especially travelers’ diarrhea, continue to rank at the top of travel-
related health problems in all international travelers.5,23 It is important to advise business 
travelers on basic precautions, including hand hygiene and choice and preparation of food 
and beverages, although the effectiveness of pre-travel advice in reducing travel-related 
diarrhea appears poor.22
Dermatologic diagnoses were the third most frequent syndromic group. (Tables 2–3) Some 
reports have suggested that business travelers experience dermatologic problems less 
frequently than tourist travelers, specifically cutaneous larva migrans, insect bites, and 
allergic or generalized rash.5,24,25 Nonetheless, 7% of 226 international business travelers 
employed by the Coca Cola Company responding to a survey reported using a topical 
antibiotic or hydrocortisone cream during their trip.26 Although specific etiologies of rashes 
were not reported, self-treatable and superficial skin conditions appeared frequent, which 
supports advising business travelers to carry these over-the-counter medications for self-
management and also when to seek medical evaluation.
For expatriate business travelers, malaria, dengue, gastrointestinal problems and respiratory 
illness were the most frequent diagnoses, illustrating the risks resulting from increased 
exposure to host-country environmental risks and lifestyle choices.27 A frequent challenge 
for expatriate travelers is adherence to malaria chemoprophylaxis; expatriates discontinue 
prophylaxis progressively over time during residence abroad,28,29 so travel medicine 
specialists should consider prescribing standby emergency malaria self-treatment. For 
expatriate business travelers, preparation should include comprehensive travel insurance 
including adequate coverage for medical, surgical, and dental healthcare abroad, 24-h 
emergency telephone access and emergency medical evacuation from their destinations, and, 
optimally, availability of local service providers to assist in non-critical medical problems.
Business travelers have been consistently identified as a high-risk group for acquiring STIs.
30–33
 Matteelli et al. found that business travel was the most frequent reason for travelers 
with STI diagnoses seen during travel, accounting for 62.5%.30 Our analysis identified a 
small proportion of psychological problems in business travelers, despite reports that 
precipitation or aggravation of psychological disorders have been the most frequent causes 
for failure of overseas assignments and repatriation among business travelers,34,35 and that 
frequent international travel has been associated with increased insurance claims for 
psychological illness.36 This analysis illustrates that GeoSentinel surveillance is less 
sensitive at detecting STIs, non-infectious conditions and psychological illness.
Our data did not capture whether the travelers were evacuated for severe disease. Among 
business travelers, analysis of nearly 1 million trips showed that one trip in 36 000 required 
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evacuation (1 in 6400 for ‘high-risk’ destinations).3 Among 504 patients evacuated by a 
single German medical evacuation service, the majority were for trauma (26%), stroke 
(15%), and myocardial infarction (8%), with less frequent infectious causes being 
pneumonia (3%) and meningitis (1%).37 For Shell International employees, medical 
evacuation occurred at a rate of 4 per 1000 during 2008–2012, most frequently for trauma 
(18%), digestive (14%), musculoskeletal (12%), cardiac (11%) and neurological (9%) 
diagnoses.38 Importantly, 9% were due to acute complications of a pre-existing diagnosis, 
illustrating the value of pre-travel health assessments and stabilization of any underlying 
condition.38 The risk of hospitalization and evacuation of expatriate workers has been 
strongly linked to the World Health Organization Human Development Index for the 
destination country.39 We found that expatriate workers appear less likely to require 
evacuation for medical problems than non-expatriate business travelers, perhaps due to more 
stringent screening, better knowledge of local resources, and better local support structures, 
or reporting bias.
The GeoSentinel database does not distinguish among the diverse population of business 
travelers or employment status, and lacks details of occupation, activities, and exposures. In 
this heterogeneous population, future data collection will benefit from more detailed 
occupational information to ascertain whether certain groups are at increased risk of 
illnesses. To refine the classification of business travelers in the GeoSentinel database, data 
collection will be revised to delineate whether the traveler is a family member 
accompanying a business traveler. Also, GeoSentinel sites are mainly outpatient clinics and, 
thus, may under-report travelers who are hospitalized subsequent to their outpatient 
evaluation at GeoSentinel sites; information such as malaria chemoprophylaxis taken may be 
incomplete or biased. Moreover, the sites specialize in tropical and travel medicine and 
infectious diseases, and typically do not capture trauma and injury, and likely also 
underestimate other problems such as psychological issues and STIs that are evaluated in 
other centers outside the GeoSentinel network. Finally, denominators of travelers are 
lacking, and descriptive analysis cannot derive rates of risk.
The strength of our analyses is that we provide robust, systematic, clinician-verified 
diagnoses on more than 12 000 business travelers from all continents, with supporting 
demographic and geographic details.
Conclusion
Diarrheal illness is a major cause of morbidity in business travelers; clear advice on 
travelers’ diarrhea prevention and self-treatment should be provided. Malaria contributes to 
significant morbidity and mortality in both non-expatriate and expatriate business travelers, 
is associated with high hospitalization rates and fatalities, and is a particular risk for the 
business traveler to sub-Saharan Africa. Underuse or non-use of malaria chemo-prophylaxis 
contributes to the problem, and new approaches to improve adherence are needed. Deaths in 
business travelers could likely be reduced by improving adherence to malaria 
chemoprophylaxis, targeted vaccination for vaccine-preventable diseases, and provision of 
advice to avoid contaminated food and drink. Given the severity and mortality associated 
with identified malaria cases and vaccine-preventable diseases, it is critical to engage the 
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employers. To optimize prevention, occupational health programs could seek ways to 
improve adherence to malaria chemoprophylaxis, target immunizations, and provide advice 
to avoid contaminated food and drink. Non-infectious disease hazards, not reflected in 
GeoSentinel data, might have even greater impact on business travelers. Our analysis shows 
that pre-travel health advice is currently under-utilized (or not provided) by business 
travelers, and our findings provide an evidence base to support geographically tailored 
guidelines for occupational medicine clinicians and business travelers.
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Appendix to Methods: Excluded Diagnoses
• Non-infectious diagnoses with no plausible relationship to travel were excluded 
(236 diagnoses): hypertension, asthma, hemorrhoids, diabetes, hepatitis, chronic 
unspecified, autoimmune disorders, heart disease, arrhythmia, heart disease, 
coronary artery disease, angina, heart disease, other, cancer, hematologic, cancer, 
celiac disease, fibromyalgia, cirrhosis, hernia, palpitations, Crohn’s disease, 
multiple sclerosis, chronic obstructive pulmonary disease (COPD), congestive 
heart failure (CHF), tumor, benign superficial, transient ischemic attack (TIA), 
thyroid disease, menstrual disorder, colonic polyposis, metabolic disorder, 
ovarian cyst, thalassemia.
• Diagnoses with uncertain relationship to travel and time and place of exposure 
were excluded (245 diagnoses): latent tuberculosis, asymptomatic HIV, AIDS, 
chronic hepatitis C, chronic hepatitis B, asymptomatic hepatitis B carrier and 
pregnancy.
• Diagnoses coded as ‘Other’ were matched with existing GeoSentinel diagnoses, 
when possible. Where no corresponding eligible GeoSentinel diagnosis existed, 
the diagnosis was excluded (154 diagnoses).
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Table 1
Demographics of 12 203 business travelers evaluated after travel at GeoSentinel sites from 1997 through 2014
Characteristic N %
Agea
 20–64 11 779 97
 ≥65 424 3
Gendera
 Male 8178 67
 Female 3970 33
Patient typea
 Inpatient 1551 13
 Outpatient 10 548 86
Pre-travel encounter
 Yes 5476 45
 No 4148 34
 Don’t know/Missing 2579 21
Interval from travel to presentation, weeks
 ≤1 4646 38
 1–6 3377 27
 ≥6 1346 11
 Unknown 2834 23
Region of GeoSentinel site
 Australia/New Zealand 463 4
 Middle East 726 6
 North America 2989 24
 North East Asia 1117 9
 South America 64 1
 South Central Asia 128 1
 Southeast Asia 404 3
 Sub-Saharan Africa 166 1
 Western Europe 6146 50
Region of exposureb
 Australia/New Zealand 45 <1
 Caribbean 391 3
 Central America 504 4
 Eastern Europe 109 1
 Middle East 293 2
 North Africa 358 3
 North America 210 2
 North East Asia 731 6
 Oceania 198 2
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Characteristic N %
 South America 814 7
 South Central Asia 1732 14
 Southeast Asia 1785 15
 Sub-Saharan Africa 4490 37
 Western Europe 407 3
 Risk qualifier Expatriate 1512 12
aUp to 1% of data are missing for the variable and are not displayed in the table.
bWe excluded 1173 of 13 227 initial patients (9%) with no reported country or region of exposure; 136 (1%) included patients had unascertainable 
regions of exposure (two probable countries of exposure in two different regions).
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